Innovative Bispecific Nanobody Targeting ASGR1 and IgG for Autoimmune Disease Therapy

VHH-P218 is a humanized nanobody-based therapeutic candidate currently in the Biological Testing stage of development. This program is designed to target both asialoglycoprotein receptor 1 (ASGR1) and Immunoglobulin G (IgG), offering a dual mechanism of action for the potential treatment of autoimmune disease. By selectively binding to ASGR1 and IgG, VHH-P218 aims to modulate immune responses involved in autoimmune pathogenesis, addressing significant unmet needs in this disease category. The bispecific construct’s optimized design allows for precise targeting, reduced immunogenicity, and enhanced biological efficacy, positioning VHH-P218 as a promising next-generation biologic for autoimmune conditions.

Licensing Opportunity

VHH-P218 is available for out-licensing and partnership opportunities. We welcome inquiries from pharmaceutical and biotech organizations seeking innovative therapies in the autoimmune disease area, and invite collaboration to accelerate its development and commercialization.

Development Phase

Modality

VHH-P218 is a codon-optimized, bispecific fusion protein, structurally composed of a peptide targeting the immunoglobulin constant domain linked to a single-chain variable fragment that binds ASGR1 and an additional peptide. Expressed in Escherichia coli BL21 Star cells, VHH-P218 benefits from the unique structural features of nanobodies, including their single-domain nature, small molecular size, high solubility, and remarkable stability. These characteristics afford excellent tissue penetration and the potential for improved bioavailability compared to conventional antibodies. For autoimmune disease therapy, such advantages may result in more efficient targeting of pathogenic mechanisms, lower off-target effects, and better patient compliance due to favorable pharmacological profiles.

Target

ASGR1 and Immunoglobulin G are the dual molecular targets of VHH-P218. ASGR1 is predominantly expressed on hepatic cells and is implicated in the clearance of glycoproteins from circulation, playing an essential role in immune modulation, while Immunoglobulin G is a widely distributed immunoglobulin in serum and tissues that orchestrates key immune functions. The interplay between ASGR1 and Immunoglobulin G is highly relevant in the context of autoimmune disease, where dysregulated IgG activity often drives pathogenic immune complexes and inflammatory responses. Targeting ASGR1 and Immunoglobulin G enables VHH-P218 to potentially modulate these crucial pathways, thus offering a strategic advantage in autoimmune disease intervention. This dual-targeting approach also maximizes therapeutic utility while reducing risks of redundancy and resistance often observed with single-target therapies.

Mechanism of Action

VHH-P218 acts through a dual mechanism by directly binding to ASGR1 on target cells and the constant region of Immunoglobulin G, functioning as a selective degrader of pathological IgG. By engaging ASGR1, VHH-P218 facilitates the internalization and clearance of pathogenic IgG from systemic circulation, thereby reducing immune complex-mediated tissue damage. This mechanism is particularly relevant in autoimmune disease, where aberrant IgG contributes to ongoing inflammation and tissue injury. As a nanobody platform, VHH-P218 possesses inherent versatility for future development into antibody-drug conjugates, bispecific formats, or other engineered biologics, broadening its clinical potential across a range of immune-mediated disorders.

Autoimmune Disease

Autoimmune diseases constitute a broad group of disorders in which the body's immune system incorrectly targets self-tissues, resulting in chronic inflammation and organ damage. These conditions affect millions worldwide, presenting substantial healthcare burdens and variable clinical manifestations, from systemic lupus erythematosus and rheumatoid arthritis to organ-specific diseases. Standard treatment approaches include immunosuppressants, corticosteroids, and targeted biologics, aiming to control abnormal immune activity. However, significant limitations persist, such as suboptimal efficacy, non-specific immunosuppression, adverse effects, and the risk of disease relapse. Moreover, many patients experience inadequate disease control or treatment-related complications. There remains an urgent need for targeted, effective, and safer therapies that address underlying immunopathology without compromising overall immune defense. VHH-P218, by specifically eliminating pathogenic IgG and modulating ASGR1-mediated pathways, represents a promising therapeutic advance with the potential to meet these unmet needs, improve patient outcomes, and expand precision medicine approaches in autoimmune disease.